Table of contents
May 2006 Volume 3 No 5
Editorial
Viewpoint
Should we use incidence, survival or mortality to assess breast cancer trends in European women?
228No single indicator provides unambiguous information regarding the population burden and dynamics of breast cancer. Milena Sant and co-authors discuss the trends in incidence, survival and mortality for patients with breast cancer in Western Europe and suggest a strategy for analysis of these data.
doi:10.1038/ncponc0489 | Full Text | PDF (103K)
Research Highlights
Fat intake and risk of breast and colorectal cancers
230doi:10.1038/ncponc0462 | Full Text | PDF (101K)
Does adjuvant radiotherapy improve survival in all patients with endometrial carcinoma?
230Calcium plus vitamin D3 supplementation does not reduce risk of colorectal cancer
231doi:10.1038/ncponc0465 | Full Text | PDF (101K)
Risk of smoking-related lung cancer is affected by race and ethnicity
231Autoimmunity is associated with improved survival during interferon therapy for melanoma
232Identification of genetic anticipation in familial pancreatic cancer
232Protein biomarker signatures for accurate diagnosis of urothelial cancer
233New approach to colorectal cancer screening could avoid unnecessary colonoscopy
233Does BPSO reduce mortality in patients with BRCA mutations?
233doi:10.1038/ncponc0471 | Full Text | PDF (100K)
Aromatase inhibitor estrogen suppression is reversed by vaginal estradiol
234doi:10.1038/ncponc0472 | Full Text | PDF (105K)
A phase II trial of combined docetaxel and tumor vaccination in prostate cancer patients
234doi:10.1038/ncponc0473 | Full Text | PDF (101K)
Overexpression of p95HER2 in breast cancer is associated with poor prognosis
235Practice Points
Does trastuzumab increase the risk of isolated central nervous system metastases in patients with breast cancer?
236Antibody–drug conjugates in acute myeloid leukemia
238doi:10.1038/ncponc0478 | Full Text | PDF (101K)
Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?
240doi:10.1038/ncponc0484 | Full Text | PDF (102K)
What factors predict a favorable outcome in young children with disseminated neuroblastoma?
242doi:10.1038/ncponc0493 | Full Text | PDF (100K)
Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?
244doi:10.1038/ncponc0492 | Full Text | PDF (100K)
Reviews
Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer
248Several randomized trials have demonstrated improved survival rates and local control when concurrent cisplatin-based chemotherapy was added to radiation therapy in patients with locoregionally advanced cervical cancer. Randomized trials that investigated the administration of neoadjuvant chemotherapy before radiation therapy, however, have failed to demonstrate a benefit of this approach. Based on clinical trial evidence cisplatin-based chemoradiation should be considered a standard treatment for most patients with locoregionally advanced carcinoma of the cervix who do not have medical contraindications to this aggressive treatment.
doi:10.1038/ncponc0486 | Full Text | PDF (168K)
Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays
256Proteomics can help to define and identify patients that will most benefit from the increasing number of molecular-targeted agents. In particular, reverse phase protein microarray provides detailed information about the state of the cellular 'circuitry' from small samples such as patient biopsy specimens. This review discusses the clinical applications of this emerging technology and how it could be used to help guide individualized treatment approaches.
doi:10.1038/ncponc0485 | Full Text | PDF (486K)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
269Despite the impressive results seen in phase II trials of trastuzumab, many tumors that overexpress HER2 show resistance to the drug. Understanding the molecular mechanisms underlying primary or treatment-induced trastuzumab resistance is critical to improving the survival of patients with metastatic breast cancer with aggressive HER2 overexpressing tumors. This review discusses the novel therapeutic strategies that target the aberrant molecular pathways, and explains how these strategies could greatly improve the duration of response to trastuzumab.
doi:10.1038/ncponc0509 | Full Text | PDF (349K)
Case Study
Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum
281doi:10.1038/ncponc0482 | Full Text | PDF (206K)
